A team led by the Duke Human Vaccine Institute and the National Institute of Allergy and Infectious Diseases has tracked the evolution of HIV and the body's corresponding immune response, hoping now to turn the knowledge gained into an experimental vaccine.
Joining a wave of companies racing in the HIV vaccines space, Aelix Therapeutics announced a $12.7 million Series A round this week--and funding from Johnson & Johnson Innovation--to support work on its therapeutic HIV vaccine candidate.
With the research and knowledge aimed at developing a potential HIV vaccine continuing to mount, a team led by The Scripps Research Institute this week unveiled its research into a family of antibodies that could be capable of creating a broad response against the virus.
A team at The Scripps Research Institute in La Jolla this week said they have identified four antibodies to target weaknesses in HIV, touting an "important advance" in HIV vaccine research that could assist in developing a vaccine.
Seeking to throw support into a field that has seen recent scientific advancements, the European Commission is stepping up with funding to form the European AIDS Vaccine Initiative. The effort will set out to develop protective and therapeutic HIV vaccines by bringing together experts from 22 institutions, both public and private.
Working at the direction of esteemed HIV researcher Dr. Robert Gallo, a University of Maryland team is taking its HIV vaccine candidate to human trials. In doing so, it's joining a race that has seen no shortage of attention of late as organizations near and far have worked to battle the virus' challenging characteristics.
The search for an HIV vaccine has been long and difficult, but researchers from Johnson & Johnson, Harvard and other groups may have made a leap. J&J;'s Janssen reported encouraging results Thursday from its preclinical trial of an HIV vaccine in rhesus monkeys. Encouraging enough for the company to sponsor human studies--the first time a Big Pharma is doing so in the HIV space.
After publishing promising preclinical results, a team from the Scripps Research Institute, led by researcher William Schief, are taking their HIV vaccine candidate to federal regulators to discuss human trials.
In a win for HIV vaccine research, Duke University researchers have scored $20 million in grants from the National Institutes of Health to develop an HIV vaccine.
Researchers have launched a clinical trial in South Africa--dubbed HVTN 100--to evaluate a candidate HIV vaccine regimen for safety and the immune response it triggers.